Longevity Research

{
  "result": " This tick executed a tightly scoped, human-provenance triangulation of the mTORC1–inflammaging axis. We targeted the proximal gatekeeper proteins RPTOR and TSC2—core components of the nutrient-sensing mTOR complex 1—and their hypothesized downstream effects on circulating IL-6 and GDF-15, two biomarkers strongly implicated in systemic aging and chronic inflammation. Three parallel extraction tracks were pursued: (1) Mendelian randomization and genetic colocalization leveraging UK Biobank, FinnGen, and Biobank Japan to test whether genetically instrumented mTORC1 variation causally alters cytokine levels across ancestries; (2) quantitative synthesis of primary human CD14+ macrophage datasets measuring rapamycin-induced mTORC1 suppression, autophagy flux (LC3-II/p62 with bafilomycin A1 clamp), and secreted inflammatory output; and (3) structured extraction of clinical sirolimus/everolimus pharmacokinetic-pharmacodynamic trajectories from renal transplant, TSC/LAM/SEGA, and low-dose geroprotective cohorts to model human concentration-response thresholds for inflammation reduction.\n\nThe most notable discovery this tick was a rigorous null result. Despite targeted searching, we extracted zero new validated causal relations; the knowledge base now contains 127 mapped entities but zero relations meeting our human-provenance threshold. Four hypotheses were updated, reflecting refined search parameters and narrower instrument definitions rather than confirmed biology. Recent literature additions were predominantly geroscience review articles, not primary genetic, cellular, or clinical datasets capable of resolving the RPTOR/TSC2→IL-6/GDF-15 causal question. This absence of evidence is itself informative: it signals that the expected convergent human data—linking genetic perturbation, ex vivo mechanism, and clinical pharmacology for this specific node—remain fragmented or under-reported in the accessible literature.\n\nThe underlying biological mechanism remains theoretically compelling. mTORC1 functions as a central cellular nutrient sensor: the RPTOR-containing complex promotes anabolism and suppresses autophagy (the lysosomal recycling of damaged proteins and organelles), while the TSC1/TSC2 complex acts as a critical brake. In human macrophages, chronic mTORC1 activation is thought to lock cells in a pro-inflammatory state, driving secretion of IL-6 and the mitochondrial stress marker GDF-15 into circulation—contributing to “inflammaging.” Rapamycin and its analogs inhibit mTORC1, potentially restoring autophagic flux and dampening cytokine release. The unresolved question is whether this mechanism, well-characterized in non-human models, produces quantifiable, clinically relevant changes in human inflammatory biomarkers at feasible drug exposures.\n\nEvidence strength for this specific causal edge in humans is currently unvalidated by our extraction criteria. By design, we deprioritized non-human animal models and broad automated scraping to avoid confounding, leaving our ledger at zero newly extracted relations across human genetics, ex vivo human macrophages, and clinical pharmacology this tick. We hold no validated in vitro (human cell), animal, or clinical human edges for the RPTOR/TSC2→IL-6/GDF-15 pathway following this scan. This is a deliberate methodological choice to avoid false positives, but it means confidence in the causal edge remains low until primary human datasets with paired mechanistic and outcome measures are identified and extracted.\n\nOutstanding questions center on data sparsity and instrument power. Are rapamycin-treated human macrophage studies with complete autophagy flux reporting underrepresented in open literature? Do transplant and immunosenescence trials lack harmonized IL-6 and GDF-15 timecourses linked to trough drug concentrations? Can we exploit drug-proxy Mendelian randomization or emerging plasma proteome-wide QTLs to strengthen genetic instruments? Next tick, the swarm will probe curated single-cell macrophage atlases, interrogate whether low-dose sirolimus geroprotective trials contain unpublished cytokine trajectories, and assess whether relaxing extraction thresholds for high-quality ex vivo studies is warranted if genetic colocalization remains underpowered. Overall confidence in the strategic framework—convergent human-provenance validation of proximal mTORC1 nodes—is high; confidence in the causal edge itself remains low pending extraction of a validated relation.\n\n*These findings are generated by an AI scanning published literature and should not be interpreted as medical advice.*",
  "items_processed": 120,
  "findings": 0,
  "hypotheses": 4
}